Related by context. All words. (Click for frequent words.) 74 colorectal cancer 69 hepatocellular carcinoma 69 renal cell carcinoma 69 liver cancer 67 metastatic breast cancer 67 metastatic cancer 66 NSCLC 66 gastric cancers 66 rectal cancers 66 hepatocellular carcinoma HCC 66 colorectal cancers 66 cancers 66 colon cancer 65 gastrointestinal cancers 65 bladder cancer 65 metastatic disease 65 ovarian cancer 65 malignant pleural mesothelioma 65 ovarian cancers 64 carcinoma 64 prostate cancers 64 adenocarcinoma 64 pancreatic adenocarcinoma 64 rectal cancer 64 metastases 64 colorectal cancer CRC 63 colorectal tumors 63 metastatic prostate cancer 63 HNSCC 63 malignancies 63 malignancy 63 bladder cancers 63 metastatic colorectal cancer 63 distant metastases 63 distant metastasis 63 CaP 63 endometrial cancer 63 breast carcinoma 63 tumor recurrence 63 HER2 positive 62 melanoma 62 nasopharyngeal carcinoma 62 pancreatic cancers 62 prostate cancer 62 gastric adenocarcinoma 62 hepatocellular cancer 62 Gastric cancer 62 nonsmall cell lung cancer 61 metastatic 61 breast cancers 61 brain metastases 61 pancreatic cancer 61 soft tissue sarcomas 61 lung tumors 61 endometrial cancers 61 carcinomas 61 advanced NSCLC 61 HER2 positive breast cancer 60 lung cancer 60 squamous cell carcinoma 60 oesophageal cancer 60 liver fibrosis 60 oropharyngeal cancer 60 metastatic colon cancer 60 solid tumors 60 colorectal 60 lobular carcinoma 60 metastatic pancreatic cancer 60 esophageal cancers 60 periodontitis 60 liver metastases 60 recurrent colorectal cancer 60 multiple myeloma 60 colon cancers 60 H. pylori infection 60 PCa 60 chronic lymphocytic leukemia CLL 59 neoplasia 59 chronic HBV infection 59 liver metastasis 59 HCV infection 59 metastatic RCC 59 SCCHN 59 cancer 59 carcinoid tumors 59 adenocarcinomas 59 metastasis 59 metastatic renal cell carcinoma 59 esophageal squamous cell carcinoma 59 gastric carcinoma 59 metastatic melanoma 59 sarcoma 59 prostate cancer CaP 59 invasive breast cancer 59 prostate cancer CRPC 59 neuroendocrine tumors 59 ovarian carcinoma 59 peritoneal carcinomatosis 59 uterine cancers 59 esophageal cancer 59 recurrent NSCLC 59 breast cancer 59 cholangiocarcinoma 59 pleural mesothelioma 59 breast cancer recurrence 58 situ LCIS 58 acute myelogenous leukemia AML 58 lymph node metastases 58 NAFLD 58 prostate carcinoma 58 mRCC 58 adenoma 58 malignant lymphoma 58 gastrointestinal stromal tumor 58 esophageal adenocarcinoma 58 lung cancers 58 GISTs 58 ADPKD 58 bowel cancers 58 locoregional 58 colorectal carcinoma 58 metastatic gastric 58 basal cell carcinoma BCC 58 Barrett esophagus 58 urothelial carcinoma 58 prostate cancer PCa 58 medullary thyroid cancer 58 operable breast cancer 58 advanced hepatocellular carcinoma 58 cutaneous melanoma 58 prostate adenocarcinoma 58 tumors 58 mCRC 58 recurrent ovarian cancer 58 stage IIIB 58 follicular lymphoma 57 metastatic bladder 57 localized prostate cancer 57 glioblastoma 57 lymphomas 57 renal tumors 57 CLL 57 premalignant 57 cell lung cancer 57 gefitinib 57 sorafenib 57 hormone receptor positive 57 multiple myeloma MM 57 relapsed ovarian cancer 57 malignant melanoma 57 grade gliomas 57 erlotinib 57 epithelial ovarian cancer 57 HER2 positive metastatic breast 57 nonmelanoma skin cancers 57 metastatic colorectal 57 transitional cell carcinoma 57 cervical carcinoma 57 unresectable 57 BRCA mutations 57 diffuse gastric 57 castration resistant prostate cancer 57 GIST 57 Helicobacter pylori infection 57 squamous cell carcinomas 57 Hepatocellular Carcinoma HCC 57 neoplasm 57 fallopian tube carcinoma 57 colorectal polyps 57 leukemia AML 57 atherosclerotic disease 57 peritoneal cancer 57 malignant neoplasms 57 bowel cancer 57 breast tumors 57 CMV disease 57 GIST tumors 56 clinically localized prostate 56 lymphoma 56 TACE 56 chemoradiotherapy 56 colorectal adenoma 56 bone metastasis 56 metachronous 56 invasive carcinoma 56 basal cell carcinomas 56 antitumor effect 56 papillary renal cell carcinoma 56 myelodysplastic syndrome MDS 56 colorectal adenomas 56 soft tissue sarcoma 56 metastatic lung cancer 56 IV NSCLC 56 bladder tumors 56 polyp recurrence 56 acute myeloid leukemia 56 urothelial cancer 56 adjuvant therapy 56 breast carcinomas 56 nonalcoholic steatohepatitis NASH 56 hormone refractory prostate cancer 56 B CLL 56 prostrate cancer 56 intestinal polyps 56 epithelial tumors 55 gastrointestinal stromal tumors 55 lymphadenectomy 55 EGFR mutation 55 malignant tumors 55 venous thrombosis 55 secondary hyperparathyroidism 55 H. pylori 55 neoadjuvant treatment 55 HRPC 55 lobular breast cancer 55 adjuvant chemotherapy 55 mCRC patients 55 cell carcinoma 55 liver disease 55 neoadjuvant therapy 55 nasopharyngeal cancer 55 serous ovarian cancer 55 trabectedin 55 severe oral mucositis 55 renal carcinoma 55 pancreatic NET 55 nonmelanoma skin cancer 55 acute leukemias 55 Stomach cancer 55 nodal metastases 55 cetuximab 55 Cholangiocarcinoma 55 pheochromocytoma 55 lymphoma CTCL 55 geographic atrophy 55 PCNSL 55 medulloblastoma 55 uveal melanoma 55 testicular cancers 55 ependymoma 55 endometrial tumors 55 mesotheliomas 55 H pylori 55 biliary tract cancer 55 laryngeal cancer 55 squamous cell 55 irinotecan chemotherapy 55 colorectal lung 55 squamous cell carcinoma SCC 55 metastatic ovarian cancer 55 adjuvant radiotherapy 55 Wilms tumor 55 cardiovascular disease 55 pancreatic tumor 55 metastatic cancers 55 MALT lymphoma 55 systemic scleroderma 55 metastatic HER2 positive 55 gemcitabine 55 metastatic GIST 55 fibrosis 55 tumors GIST 55 renal cell carcinomas 55 nonmetastatic 55 neoadjuvant chemotherapy 55 urinary bladder cancer 55 differentiated thyroid 55 lobular cancer 55 thromboembolic events 55 SHPT 55 endometrial hyperplasia 55 osteosarcomas 55 grade cervical intraepithelial 55 colorectal gastric 55 adenomas 55 neoplastic lesions 55 intestinal metaplasia 54 H. pylori eradication 54 BRCA2 mutations 54 papillary thyroid cancer 54 lung adenocarcinoma 54 premalignant lesions 54 adenomatous polyps 54 recurrent prostate cancer 54 squamous cell cancer 54 cisplatin chemotherapy 54 liver resection 54 neoplasms 54 seminoma 54 colorectal liver metastases 54 micrometastases 54 malignant growths 54 metastatic malignant melanoma 54 prostate cancer mCRPC 54 precursor lesions 54 hypercholesterolemia 54 temsirolimus 54 systemic lupus erythematosus 54 candidemia 54 colorectal neoplasia 54 VTE 54 gastroesophageal junction 54 leukemia ALL 54 oesophageal adenocarcinoma 54 lung colorectal 54 breast endometrial 54 pancreatic islet cell 54 prostate cancer AIPC 54 HER2 positive cancers 54 PAOD 54 neuroendocrine carcinoma 54 vinorelbine 54 heavily pretreated 54 lupus nephritis 54 biochemical recurrence 54 lymph node involvement 54 lymph node dissection 54 postmenopausal breast cancer 54 angiosarcoma 54 chronic lymphocytic leukemia 54 mucinous 54 lung metastases 54 advanced adenoma 54 Glioblastoma Multiforme 54 pancreatic carcinoma 54 sorafenib Nexavar 54 Metastatic breast cancer 54 squamous cell cancers 54 Velcade bortezomib 54 thymoma 54 invasive ductal 54 KRAS wild 54 T1a 54 metastatic malignant 54 non Hodgkin lymphoma 54 squamous cell lung cancer 54 carcinoid tumor 54 prostate cancer HRPC 54 grade glioma 54 gastrointestinal stromal tumor GIST 54 Metastatic 54 Crohn disease 54 diabetes mellitus 54 bone metastases 54 metastatic lesions 54 ccRCC 54 familial pancreatic cancer 54 HBeAg negative 54 sunitinib 54 papillary 54 chemoradiation 54 TEMODAL 54 gastrectomy 54 severe sepsis 54 non squamous NSCLC 54 essential thrombocythemia 54 axillary lymph nodes 54 intravesical therapy 54 Barrett esophagus BE 53 PSADT 53 AA amyloidosis 53 histological subtype 53 diabetic nephropathy 53 gefitinib Iressa 53 hyperphosphatemia 53 IV melanoma 53 refractory ovarian cancer 53 invasive ductal carcinoma 53 ductal cancer 53 metastatic adenocarcinoma 53 gemcitabine chemotherapy 53 Nexavar tablets 53 oesophageal 53 epithelial ovarian 53 MGUS 53 radical nephrectomy 53 melanomas 53 carcinoid 53 Waldenstrom macroglobulinemia 53 platinum refractory 53 rs# [002] 53 atypical hyperplasia 53 CMV infection 53 chronic ITP 53 metastatic renal cell 53 APOL1 53 epithelial cancers 53 hepatic fibrosis 53 cisplatin resistant 53 stage IIIA 53 cell carcinomas 53 refractory multiple myeloma 53 receptor tyrosine kinase inhibitor 53 metastatic NSCLC 53 Adenocarcinoma 53 bile duct cancers 53 metastatic carcinoma 53 glioma 53 polycythemia vera 53 invasive bladder 53 coronary disease 53 carcinoid cancer 53 pancreatic lung 53 cell lymphomas 53 Amrubicin 53 colon rectal 53 cutaneous squamous cell carcinoma 53 invasive cervical cancer 53 bronchogenic carcinoma 53 EGFR inhibitors 53 HCV infections 53 chronic pancreatitis 53 GBM tumors 53 trastuzumab 53 colorectal adenocarcinoma 53 Burkitt lymphoma 53 olaparib 53 completely resected 53 pancreatic 53 tumor subtypes 53 ulcerative colitis 53 colorectum 53 S. aureus infections 53 antigen PSA 53 colo rectal cancer 53 pegylated liposomal doxorubicin 53 ErbB2 positive 53 KRAS mutation 53 Acute Myelogenous Leukemia AML 53 AAT deficiency 53 EGFR mutations 53 OPAXIO 53 hepatocellular carcinomas 53 lymph node metastasis 53 unresectable liver cancer 53 leukemia CLL 53 invasive candidiasis 53 androgen independent 53 pelvic lymphadenectomy 53 pulmonary metastases 53 sentinel node 53 Mantle Cell Lymphoma 53 EGFR 53 skeletal metastases 53 liver transplant recipients 53 locoregional recurrence 53 superficial bladder cancer 53 thyroid nodules 53 IV malignant melanoma 53 recurrent VTE 53 medulloblastomas 53 prognostic indicator 53 Helicobacter pylori 53 Halaven 53 ovarian lung 53 myeloid leukemia 52 Chronic lymphocytic leukemia 52 chronic periodontitis 52 myeloproliferative disorders 52 recurrent glioblastoma multiforme 52 Carcinoma 52 advanced adenomas 52 cardiovascular disease CVD 52 contralateral breast 52 hepatitis C infection 52 hematologic malignancies 52 Doxil ® 52 pancreatic neuroendocrine tumors 52 hepatorenal syndrome 52 Afinitor 52 unresectable stage 52 CC genotype 52 thyroid carcinoma 52 relapsed SCLC 52 colon tumors 52 recurrent metastatic 52 HGPIN 52 T2DM 52 lymphocytic leukemia 52 mutated KRAS gene 52 prostate tumor 52 metastatic kidney 52 pulmonary arterial hypertension PAH 52 ductal adenocarcinoma 52 Glioblastoma Multiforme GBM 52 acute promyelocytic leukemia 52 osteosarcoma 52 refractory CTCL 52 BCG refractory 52 advanced unresectable 52 adjuvant radiation 52 cranial irradiation 52 tumor progression 52 distal colon cancer 52 inflammatory bowel disease 52 bevacizumab Avastin 52 cerebral infarction 52 axitinib 52 ductal breast cancer 52 breast pancreatic 52 scleroderma 52 CLL SLL 52 acid secretion 52 glioblastoma multiforme GBM 52 follicular thyroid cancer 52 atherosclerotic lesions 52 Alessandro Riva 52 thyroid cancers 52 atypia 52 Non Hodgkin lymphoma 52 esophageal carcinoma 52 Torisel 52 resistant ovarian cancer 52 adenoid cystic carcinoma 52 ovarian breast 52 Bladder cancer 52 paraganglioma 52 indolent NHL 52 TORISEL 52 Irinotecan 52 refractory colorectal cancer 52 EGFR tyrosine kinase inhibitors 52 Hepatocellular Carcinoma 52 breast cancer metastasis 52 cell lymphoma ALCL 52 HER2 + 52 Proxinium TM 52 acute promyelocytic leukemia APL 52 lymphadenopathy 52 precancerous lesions 52 Sezary syndrome 52 proliferative diabetic retinopathy 52 PGDH 52 chronic HCV 52 bevacizumab 52 taxane therapy 52 esophageal tumors 52 chlorambucil 52 precancerous lesion 52 symptomatic BPH 52 prostate pancreatic 52 alcoholic hepatitis 52 cardiac dysfunction 52 BRAF mutation 52 liver transplantation 52 cirrhosis liver failure 52 cancer mCRC 52 DLBCL 52 oral mucositis 52 papillary thyroid carcinoma 52 cytoreduction 52 systolic dysfunction 52 transthyretin amyloidosis 52 evaluating T DM1 52 lipid abnormalities 52 atherosclerosis 52 anaplastic 52 gallstone disease 52 hepatoma 52 basal cell nevus syndrome 52 hypercalcemia 52 allogeneic bone marrow 52 nonalcoholic steatohepatitis 52 HER2 overexpression 52 situ CIS 52 neoadjuvant 52 PNET 52 chemoradiation therapy 52 cardiotoxicity 52 ovarian tumors 52 recurrent glioblastoma 52 NSABP 52 cirrhosis 52 myelofibrosis MF 52 neuroblastomas 52 testicular germ cell 52 posaconazole 52 myelodysplastic syndromes MDS 52 haematological cancers 52 HER2 52 squamous 52 chronic rhinosinusitis 52 trans retinoic acid 52 postoperative delirium 52 eribulin mesylate 52 preoperative chemotherapy 52 pCR 52 rectal carcinoma 52 CTEPH 52 dasatinib 52 cardiovascular mortality 52 colorectal neoplasms 51 node metastases 51 Acute myeloid leukemia 51 mucosal lesions 51 Multiple Myeloma 51 unresectable tumors 51 ALCL 51 castrate resistant prostate cancer 51 leukaemias 51 atrophic gastritis 51 carcinoma HCC 51 bladder carcinoma 51 multicentric 51 Prognostic factors 51 hepatic metastases 51 resectable 51 NSCL cancer 51 cisplatin 51 metastatic castration resistant 51 nasopharyngeal carcinoma NPC 51 acute GVHD 51 disease progression 51 ovarian pancreatic 51 CTCL 51 acute myeloid leukemia AML 51 axillary dissection 51 Kaposi sarcoma 51 micrometastasis 51 chronic HBV 51 periodontal disease 51 carcinoma HNSCC 51 macroalbuminuria 51 leukemias 51 MYCN amplification 51 colon carcinoma 51 total thyroidectomy 51 relapsed multiple myeloma 51 CIN3 51 leiomyomas 51 Radical prostatectomy 51 sorafenib Nexavar ® 51 parathyroid carcinoma 51 node metastasis 51 mycophenolate mofetil 51 synovial sarcoma 51 Idiopathic Pulmonary Fibrosis 51 cell lymphoma CTCL 51 tumor 51 DCIS 51 activating mutations 51 dysglycemia 51 lung carcinomas 51 bendamustine 51 acute coronary syndrome 51 gliomas 51 fallopian tube cancers 51 unresectable locally advanced 51 PKCi 51 Sjögren syndrome 51 myeloproliferative diseases 51 HER2 negative 51 microsphere therapy 51 Papillary 51 subependymal giant cell 51 breast ovarian 51 assessing T DM1 51 SIR Spheres microspheres 51 medically inoperable 51 adenomatous 51 hamartomas 51 atopic dermatitis 51 gastric lymphoma 51 malignant transformation 51 postoperative chemotherapy 51 cervical dysplasia 51 SSc 51 Adjuvant chemotherapy 51 inoperable pancreatic cancer 51 Candida infections 51 Raf MEK ERK 51 abdominal adiposity 51 idiopathic pulmonary fibrosis IPF 51 cardiovascular morbidity 51 anti angiogenic therapy 51 imatinib therapy 51 invasive lobular 51 histologic subtype 51 resected pancreatic cancer 51 sarcomatoid 51 cytoreductive nephrectomy 51 urolithiasis 51 Apaziquone 51 cirrhotic patients 51 Tavocept 51 relapsing remitting MS RRMS 51 idiopathic myelofibrosis 51 metastatic basal cell 51 contralateral breast cancer 51 depsipeptide 51 hematopoietic cancers 51 imatinib Gleevec 51 astrocytoma 51 Atypical Hemolytic Uremic Syndrome 51 lymph node removal 51 AML MDS 51 Li Fraumeni Syndrome 51 brain tumors 51 chronic HCV infection 51 sarcomas 51 carotid stenosis 51 thromboembolic 51 non squamous 51 endometrial carcinoma 51 Squamous 51 prognostic marker 51 non metastatic osteosarcoma 51 myelodysplastic syndromes 51 hematologic disorders 51 erlotinib Tarceva ® 51 prostate lung 51 afatinib 51 disease 51 myeloproliferative disorder 51 nephropathy 51 papillary RCC 51 pneumonectomy 51 Haptoglobin 51 vandetanib 51 imatinib 51 lymphatic tissue 51 stage IIIB IV 51 malignant gliomas 51 liver cirrhosis 51 Hurler syndrome 51 LHRH receptor positive 51 elevated triglyceride levels 51 malignant mesothelioma 51 CTAP# Capsules 51 prognostic variables 51 cutaneous T cell 51 ovarian 51 dyslipidemia 51 Acute Myeloid Leukaemia AML 51 haematopoietic 51 pancreatic prostate 51 IV metastatic melanoma 51 smoldering myeloma 51 Renal Cell Carcinoma RCC 51 neck squamous cell 51 situ DCIS 51 biliary tract cancers 51 tuberous sclerosis TS 51 azacitidine 51 skin cancers 51 cervical lesions 51 lymphoproliferative disorders 51 chemoprevention 51 metastatic relapsed 51 biliary cancer 51 atherothrombotic events 51 Barrett Esophagus 51 CYT# potent vascular disrupting 51 astrocytomas 51 invasive fungal infection 51 sporadic ALS 51 urothelial bladder cancer 51 Hurthle cell 51 prostate tumors 51 Hodgkin lymphoma HL 51 BRCA mutation carriers 51 Malignant Melanoma 51 pre cancerous polyps 51 NMIBC 51 chlamydial infection 51 follicular lymphoma FL 51 lung pancreatic 51 adecatumumab 51 histologically confirmed 51 Wegener granulomatosis 51 adjuvant therapies 51 fibroadenomas 51 severe neutropenia 51 FSGS 50 B7 H3 50 acromegaly 50 EGFr 50 mycosis fungoides 50 pancreatectomy 50 Candida infection 50 gastrointestinal stromal tumors GIST 50 BRCA2 mutation 50 ALND 50 YONDELIS 50 Nexavar sorafenib 50 vascular disease 50 transplantation HCT 50 PITX2 50 hormone refractory 50 chronic hepatitis B 50 diabetic gastroparesis 50 Surgical resection 50 HER2 amplification 50 neoplasias 50 cervical lymph nodes 50 SLNB 50 metastatic pancreatic 50 digestive tract cancers 50 ischemic stroke 50 cancerdefine 50 EpCAM 50 hormone receptor negative 50 chemoresistance 50 metastatic tumors 50 malignant ascites 50 Renal cell carcinoma 50 anthracyclines 50 hepatic cirrhosis 50 renal disease 50 5-FU/LV 50 atherothrombotic disease 50 antiangiogenic therapy 50 androgen deprivation 50 chronic ITP patients 50 docetaxel 50 ERCC1 50 malignant pancreatic 50 coronary artery disease 50 bronchiectasis 50 HBV infection 50 cell lymphoma 50 polycythemia vera PV 50 extranodal 50 basal cell carcinoma 50 choriocarcinoma 50 duodenal ulcers 50 WT1 50 PTLD 50 GvHD 50 Ewing sarcoma 50 B Cell Lymphoma 50 pre cancerous lesions 50 cetuximab Erbitux 50 DIPG 50 EGF receptor 50 CDH1 50 NF1 50 ASCUS 50 mTOR inhibitors 50 AA Amyloidosis 50 gynecologic cancer 50 FDG PET 50 prostate carcinomas 50 microalbuminuria 50 panobinostat 50 ThermoDox R 50 T2D 50 defibrotide 50 tumoral 50 ximelagatran 50 advanced HER2 positive 50 metastatic breast 50 chronic thromboembolic pulmonary 50 colorectal cancer liver metastases 50 Helicobacter infection 50 curative resection 50 HYVET 50 thromboembolic disease 50 clinico pathological 50 juvenile myelomonocytic leukemia 50 Tamibarotene 50 parathyroid 50 liver scarring 50 pharyngeal cancer 50 axillary lymph node 50 cediranib 50 breast colon 50 BRCA1 mutations 50 IPAH 50 cervical neoplasia 50 PARP inhibitor 50 stage IIIb IV 50 nephrectomy 50 TNFa 50 squamous cell skin 50 colorectal breast 50 decitabine 50 cystectomy 50 KRAS mutations occur 50 cytoreductive surgery 50 Vicinium TM 50 gastric cardia 50 benign breast 50 thrombosis 50 opioid induced constipation OIC 50 Gastric Cancer 50 neoadjuvant chemoradiotherapy 50 HCV genotype 50 tumor lysis syndrome 50 lung metastasis 50 eplerenone 50 Metastases 50 colorectal pancreatic 50 leukemias lymphomas 50 malignant neoplasm 50 glioblastomas 50 radiofrequency ablation RFA 50 neoplastic cells 50 sorafenib tablets 50 ASCT 50 Zolinza 50 Metastatic Colorectal Cancer 50 psoriasis 50 papillary carcinoma 50 lung colon 50 5FU 50 serum PSA 50 cinacalcet 50 Hodgkin lymphoma NHL 50 p# mutations 50 Aplidin 50 myelofibrosis 50 venous thromboembolism 50 tesetaxel 50 diabetes mellitus DM 50 chemotherapy cisplatin 50 inflammatory bowel diseases 50 irinotecan 50 carboplatin paclitaxel 50 pancreatic colon 50 immunohistochemical staining 50 uveitis 50 bevacizumab Avastin ® 50 neuroblastoma 50 small lymphocytic lymphoma 50 T1c 50 myeloma 50 gynecological cancer 50 autologous transplants 50 tyrosine kinase inhibitors 50 pouchitis 50 bacteriuria 50 oncological indications 50 penetrance 50 HSCT 50 gynecologic cancers 50 lung adenocarcinomas 50 polyps 50 K ras mutations 50 HNPCC 50 HBV 50 acute coronary syndromes 50 radiochemotherapy 50 colorectal liver 50 oesophageal cancers 50 advanced metastatic renal 50 elevated CRP 50 invasive fungal infections 50 Rectal cancer 50 endocrine therapies 50 chemoprevention trials 50 lymphocytosis 50 sentinel lymph node biopsy 50 virologic failure 50 thrombotic complications 50 AEG# 50 EUS FNA 50 HIV HCV coinfected 50 liposarcoma 50 gynecological cancers 50 androgenetic alopecia 50 vertebral fracture 50 p# biomarker 50 standard chemotherapy regimens 50 familial adenomatous polyposis 50 MGd 50 ischemic colitis 50 acute leukemia 50 localized renal 50 IGF 1R 50 neuroendocrine cancers 50 nodal metastasis 50 multidrug resistance 50 phase IIb clinical 50 myelofibrosis polycythemia vera 50 Cell Lung Cancer 50 myeloproliferative neoplasms 50 choroidal neovascularization CNV 50 ® cetuximab 50 EGFR expressing 50 advanced epithelial ovarian 50 ThermoDox ® 50 chronic granulomatous disease 50 NovoTTF 50 Taxotere R 50 systemic lupus erythematosus SLE 50 renal transplantation 50 pediatric malignancies 50 postmenopausal women 50 thyroid carcinomas 50 XELOX 50 Erlotinib 50 Everolimus 50 prostate breast 50 CIN2 50 malignant lesions 50 bilateral oophorectomy 50 HCV infected 50 Hashimoto thyroiditis